CSLLY · Csl Ltd
Price & Indicators
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CSLLY
this stock
Csl Ltd
|
$44.14B | -19.3% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$453.48B | +6.3% | +22179.2% | 697.3 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$119.47B | +5.6% | +46.2% | 27.5 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$78.17B | -1.2% | +20.8% | 18.8 | 3.4% |
|
ARGX
Argenx SE
|
$54.30B | +0.4% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CSLLY | +8.9% | +5.9% | -21.2% | +6.1% | -19.3% |
| SPY | +4.1% | +3.2% | +11.4% | +3.3% | +13.1% |
| vs SPY | +4.8% | +2.7% | -32.6% | +2.9% | -32.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.